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dose increase to 2.7 mg/kg was implemented, leading to the 
achievement of levels more in-line with those previously 
reported. This increased dose level was well tolerated over 
six courses of treatment, resulting in a good response to 
cisplatin monotherapy and the patient remains in remission 
at 3.5 years. In contrast, a 50 % vincristine dose reduction 
for weight in a 3-week-old neonate resulted in plasma con-
centrations comparable to levels observed in older children, 
leading to successful treatment and continued remission at 
2 years. In a third patient, etoposide and carboplatin clear-
ance values normalised to body weight were comparable to 
those reported in older children, resulting in comparatively 
lower exposures following reduced dosing.
Conclusions The current report provides unique data on 
the pharmacokinetics of several widely used anticancer 
drugs in neonates treated within the first few weeks of life. 
The provision of these data acts as a useful reference point 
to support future dosing decisions to be made by clinicians 
in the treatment of these challenging patients.
Keywords Neonates · Chemotherapy · Hepatoblastoma · 
Neuroblastoma · Wilms’ tumour · Cisplatin · Vincristine · 
Carboplatin · Etoposide · Therapeutic drug monitoring
Introduction
Selection of the most appropriate dosing regimen to 
administer to neonates within the first few weeks of 
life represents a significant clinical dilemma. Develop-
mental physiological changes that occur following birth 
have the potential to significantly impact drug disposi-
tion and therefore the likely clinical outcome, in terms 
of observed response and toxicity [1, 2]. It is therefore 
a concern that there currently exists a lack of scientific 
Abstract 
Purpose Selection of the most appropriate chemotherapy 
dosing regimens for neonates treated within the first weeks 
of life represents a significant clinical dilemma. Due to a 
lack of information relating to the clinical pharmacology of 
anticancer drugs in these challenging patients, current dos-
ing guidelines are based on limited scientific rationale. In 
the current study, we investigate the utilisation of therapeu-
tic drug monitoring approaches in neonates with localised 
hepatoblastoma, Wilms’ tumour and stage 4S neuroblas-
toma, being treated with widely used anticancer drugs.
Methods Plasma concentrations of cisplatin, vincristine, 
etoposide and carboplatin were quantified in two neo-
nates being treated within the first 3 weeks of life and in 
a 32-week preterm infant treated at a gestational age of 
40 weeks. Therapeutic drug monitoring was carried out 
where appropriate, based on the pharmacokinetic data 
obtained in conjunction with clinical response and toxicity.
Results Treatment of a child aged 2 weeks with a recom-
mended cisplatin dose reduction for weight to 1.8 mg/kg 
resulted in achievement of unbound cisplatin plasma con-
centrations of 0.01–0.08 µg/mL, markedly lower than expo-
sures previously reported in infants and older children. A 
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rationale and standardisation for many well established 
drugs, in terms of the dosing regimens implemented 
for these very young infants, with many commonly uti-
lised regimens largely defined for children between 3 
and 12 months of age [3]. Markedly reduced dosing 
would appear to be a widely accepted approach in these 
patients, largely driven by concerns over an increased 
susceptibility to the side effects of treatment in develop-
ing neonates and/or the premise that drugs will be han-
dled differently than in older children in terms of drug 
disposition. However, in the vast majority of cases there 
would appear to be limited scientific rationale on which 
to base these assumptions.
There currently exist relatively limited data concerning 
anticancer drug disposition in the neonatal patient popu-
lation. While some excellent review papers in this area 
have previously been published, they highlight the dearth 
of information currently available from pharmacokinetic 
studies in infant patients per se and a complete lack of data 
generated from studies within the first few weeks of life for 
all but a handful of anticancer drugs [4, 5]. Where studies 
have been carried out, drug disposition has generally been 
shown to differ from that observed in older children and 
adults, most likely relating to the continuing development 
and maturation of renal and hepatic function in the neonate, 
which may significantly impact on drug metabolism and 
elimination [6, 7].
Previous studies carried out by our group have high-
lighted the clinical benefits of carrying out therapeutic 
drug monitoring (TDM) approaches with the anticancer 
drug carboplatin. These studies have included the treat-
ment of preterm and newborn neonates, diagnosed with 
retinoblastoma and treated within the first few weeks 
of life [8, 9]. The generation of additional pharmacoki-
netic data in this patient population, for a wider array 
of anticancer drugs and tumour types, will facilitate the 
implementation of more appropriate evidence-based dos-
ing regimens for the future treatment of neonates with 
cancer.
In the current study, we describe a series of case reports 
in neonates being treated with the anticancer drugs cispl-
atin, vincristine, etoposide and carboplatin for a range of 
tumour types within the first weeks of life. The marked 
interpatient variability previously observed for all four of 
these drugs in older children, combined with the known 
maturational changes in developing infants, provides a 
convincing case supporting the implementation of TDM 
studies with each course of therapy. Publication of these 
unique data, even in small patient numbers, will help to 
provide some guidance and rationale for the future treat-
ment of neonates with these commonly used anticancer 
drugs.
Materials and methods
Patient treatment
Three neonates being treated with various anticancer drugs 
were studied at two clinical centres in the UK. The first 
patient (001) was born full term, diagnosed with localised 
hepatoblastoma and treated with cisplatin monotherapy 
at 2 weeks of age and a body weight (BW) of 3.0 kg. The 
patient had a creatinine level of 22 µmol/L (within the nor-
mal range for this age [10]), liver function tests as measured 
by AST and ALT values of 29 and 9 U/L, respectively, and 
an albumin level of 22 g/L (all within normal ranges based 
on age [11]). An elevated bilirubin level of 199 µmol/L was 
observed (predominantly unconjugated bilirubin associ-
ated with neonatal jaundice) in addition to a highly elevated 
LDH level of 1067 U/L. An initial cisplatin dose of 5.4 mg 
(1.8 mg/kg) was administered as a 24-h intravenous infu-
sion on course 1 of treatment, and blood samples were col-
lected for quantification of cisplatin plasma concentrations. 
Prior to course 2 of treatment, the patient had a creatinine 
level of 21 µmol/L, AST and ALT values of 39 and 13 U/L, 
respectively, and an albumin level of 25 g/L (all within 
normal ranges based on age [10, 11]). The elevated biliru-
bin level measured on course 1 of treatment had reduced 
to 44 µmol/L prior to cisplatin administration on course 2. 
The dose of cisplatin was increased to 8.3 mg (2.7 mg/kg) 
on course 2 of treatment, based on the plasma concentra-
tions observed on course 1 and how the patient tolerated 
treatment, with blood samples for pharmacokinetic analysis 
again collected.
The second patient (002) was born full term and diag-
nosed with Wilms’ tumour (stage 1 intermediate risk) on 
day 2 of life. They received weekly vincristine following 
a primary nephrectomy, according to the protocol recom-
mended dose of 1.5 mg/m2 vincristine reduced by 50 % 
due to the very young age of the patient (3 weeks of age, 
BW 3.3 kg). A dose of 0.16 mg (0.05 mg/kg, 0.75 mg/
m2) was administered as a short intravenous infusion, with 
blood samples collected for quantification of vincristine 
plasma concentrations. The patient had a creatinine level 
of 46 µmol/L (within the normal range for this age [10]) 
at initiation of chemotherapy, normal liver function tests 
(ALT 17 U/L, ALP 147 U/L), a bilirubin level of 13 µmol/L 
and an albumin level of 29 g/L (within normal ranges for 
patient age [11]). Albumin levels were seen to progres-
sively increase to from 29 to 34 g/L during treatment.
The third patient (003) received carboplatin, etoposide 
and vincristine for the treatment of stage 4S neuroblas-
toma with MYCN amplification. The patient had been 
born 8 weeks premature at a gestational age of 32 weeks 
and was suffering from anuria when treated at age 8 weeks 
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(gestational age 40 weeks), with a body weight of 2.5 kg. At 
the time of treatment, the patient had a creatinine level of 
43 µmol/L (within the normal range for this age [10]), a rel-
atively low albumin level (21 g/L), elevated ALT (97 U/L) 
and elevated bilirubin (54 µmol/L), consistent with acute 
liver injury secondary to tumour and hepatic artery ligation. 
Blood samples were collected for the analysis of carbopl-
atin and etoposide plasma concentrations. Carboplatin was 
administered at a dose of 10 mg (4 mg/kg) as a 1-h intra-
venous infusion on days 1, 2 and 3 of treatment. Etoposide 
was administered as a 4-h intravenous infusion at a dose of 
8 mg (3.2 mg/kg) on day 1 and at a dose of 12.5 mg (5 mg/
kg) on days 3 and 4 of treatment, with vincristine adminis-
tered as a short intravenous infusion at a dose of 0.28 mg 
(0.11 mg/kg) on day 4 only. The patient underwent con-
tinuous veno-venous haemofiltration (CVVH) before and 
after chemotherapy due to oligo-anuria.
Patient characteristics are provided alongside details of 
individual patient treatment in Table 1. Ethical approval 
was not required for this approach to treatment, providing 
information on drug levels as a clinical request by the treat-
ing centre to be used alongside tolerability data to guide the 
selection of dosing regimens over multiple courses of treat-
ment. TDM in this setting was carried out at the request of 
the treating clinician.
Blood sampling and analysis
For patient 001, blood samples (1 mL) for pharmacokinetic 
analysis were obtained from a central line prior to cispl-
atin infusion, 6 h after the start of infusion, at 24 h (end of 
infusion) and at 8 h following the end of infusion. Plasma 
was separated from whole blood samples by centrifugation 
(1200 g, 4 °C, 10 min), and 0.5 mL was then removed and 
placed in an Amicon Centrifree micropartition unit with 
a 30,000 MW cut-off (Millipore, Edinburgh, UK). This 
sample was centrifuged (1500 g, 4 °C, 15 min) to obtain 
plasma ultrafiltrate for determination of free cisplatin lev-
els. For patient 002, blood samples (2 mL) were collected 
at 30 min, 2 h, 6 h and 24 h following a short bolus infu-
sion of vincristine, and plasma was immediately separated 
by centrifugation (1200 g, 4 °C, 10 min). For patient 003, 
blood samples were obtained before carboplatin infusion, 
30 min after the start of infusion, at 1 h (end of infusion) 
and at 1 and 2 h after the end of infusion on days 1 and 2 
of treatment. Plasma was separated from whole blood sam-
ples by centrifugation (1200 g, 4 °C, 10 min), and 0.5 mL 
was then removed for preparation of plasma ultrafiltrate as 
described above, for determination of free carboplatin lev-
els. For analysis of etoposide levels in this patient, blood 
samples were collected at 2 h after the start of infusion, at 
4 h (end infusion) and at 2 h after the end of infusion on 
day 1 of treatment, and plasma was immediately separated Ta
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by centrifugation (1200 g, 4 °C, 10 min). All samples for 
quantification of drug levels were stored at −20 °C prior to 
analysis.
Samples were sent by overnight courier, on dry ice and 
in an insulated container, to the Northern Institute for Can-
cer Research, Newcastle University. Cisplatin and carbopl-
atin pharmacokinetic analyses were carried out by flame-
less atomic absorption spectrophotometry (AAS) using a 
Perkin–Elmer AAnalyst 600 graphite furnace spectrom-
eter (Perkin–Elmer Ltd, Beaconsfield, UK). Total and free 
(unbound) platinum levels were determined in plasma and 
plasma ultrafiltrate samples, respectively, as described pre-
viously [12, 13]. All samples were analysed in duplicate, 
and values expressed as the average of these measure-
ments. Duplicate values were within 15 % of each other in 
all cases. Intra- and inter-assay coefficients of variation for 
a quality assurance sample had to be <10 % for an assay 
to be valid. The limit of detection for the AAS assay was 
0.10 µg/mL. Quantification of vincristine levels in plasma 
samples was carried out using a validated liquid chroma-
tography–mass spectrometry (LC/MS) assay, with a lower 
limit of quantification (LLOQ) of 0.50 ng/mL as previ-
ously described [14]. Etoposide plasma concentrations 
were determined using an API 2000 LC/MS assay, with a 
standard curve of 0.20–10.0 µg/mL as previously described 
[15]. Intra-assay coefficients of variation were <10 % in all 
cases.
Statistical analysis
Pharmacokinetic parameters for cisplatin, vincristine and 
etoposide were calculated by non-compartmental analysis 
using the WinNonlin software package. Carboplatin clear-
ance (Cl) and AUC were determined by Bayesian analysis 
using a two-compartment model as described previously 
[13, 16].
Results
Drug treatment and dose adjustment
Patient 001 was treated with cisplatin at 2 weeks of age 
(BW 3.0 kg) at an initial dose of 1.8 mg/kg administered 
as a 24-h intravenous infusion. Concentrations of unbound 
cisplatin measured in plasma ultrafiltrate, determined over 
a 48-h period following the start of administration, ranged 
from 0.01 to 0.08 µg/mL, with corresponding total cispl-
atin concentrations in plasma ranging from 0.19 to 0.56 µg/
mL (Fig. 1a). These levels are approximately fivefold lower 
than concentrations previously reported in childhood can-
cer patients receiving cisplatin for the treatment of hepa-
toblastoma and other tumour types [12]. Based on the low 
plasma concentrations observed on course 1 of treatment, 
the dose of cisplatin was increased by 50 % to a dose of 
2.7 mg/kg on course 2 (at 4 weeks of age) and levels again 
quantified. Following this dose increase, concentrations of 
unbound cisplatin ranged from 0.12 to 0.16 µg/mL, with 
corresponding total cisplatin concentrations in plasma 
ranging from 0.97 to 1.36 µg/mL (Fig. 1b). Table 2 shows 
the key pharmacokinetic parameters determined following 
doses of 1.8 and 2.7 mg/kg in this patient. Unbound cispl-
atin Cl values of 10.6 and 10.1 mL/min/kg were observed 
on course 1 and 2 of treatment, following doses of 1.8 
and 2.7 mg/kg, respectively, with corresponding AUC0–∞ 
values of 168 and 266 µg/mL min. These data compare 
to unbound cisplatin Cl values of 3–15 mL/min/kg and 
AUC values of 300–810 µg/mL min previously reported in 
children aged 0.5–19.3 years of age, following a dose of 
100 mg/m2 (approximately 3–5 mg/kg) cisplatin, similarly 
administered as a 24-h intravenous infusion [17]. Inclusion 
of the data obtained in the current study with these previ-
ously published data indicates an apparent relationship 
between patient BW and normalised cisplatin clearance, 
with a trend towards proportionally higher clearance values 
in smaller patients (Fig. 2). Unbound cisplatin t1/2 values 
Fig. 1  Plasma concentrations of unbound and total cisplatin meas-
ured in patient 001 following treatment with cisplatin administered as 
a 24-h intravenous infusion at a dose of 1.8 mg/kg at 2 weeks of age 
on course 1 (a) and a dose of 2.7 mg/kg at 4 weeks of age on course 
2 (b)
689Cancer Chemother Pharmacol (2016) 77:685–692 
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observed in the current study were 7.0 and 4.3 h on courses 
1 and 2 of treatment, respectively, whereas total cisplatin 
t1/2 values increased from 13.5 h on course 1 to 36.0 h on 
course 2 of treatment.
Patient 002 received vincristine at 3 weeks of age (BW 
3.3 kg), as a short intravenous infusion at a 50 % reduced 
dose level of 0.75 mg/m2, equivalent to 0.05 mg/kg. Vin-
cristine concentrations ranged from 11.2 ng/mL at 30 min 
post-infusion to 1.1 ng/mL at 24 h (Fig. 3), comparable to 
levels reported in older children (3–9 years of age) with 
Wilms’ tumour, following the recommended full dose of 
1.5 mg/m2 for children weighing >12 kg (range of 5.0–
12.4 ng/mL at 30 min and 1.1–2.3 ng/mL at 24 h) [14]. 
Vincristine pharmacokinetics calculated by non-compart-
mental analysis included a Cl of 29.8 mL/min (142 mL/
min/m2) and an AUC0–24h of 4066 ng/mL min, as compared 
to previously reported Cl values of 120–897 mL/min (169–
825 mL/min/m2) and AUC0–24h values of 1591–8310 ng/
mL min [14]. Table 3 shows the key pharmacokinetic 
parameters determined for vincristine in this patient.
Patient 003 received carboplatin, etoposide and vin-
cristine for the treatment of stage 4S neuroblastoma with 
MYCN amplification, at a gestational age of 40 weeks (BW 
2.5 kg). Plasma concentrations of carboplatin and etopo-
side were quantified on day 1, with carboplatin levels again 
analysed on day 2 of treatment. Concentrations of unbound 
carboplatin following a dose of 4 mg/kg/day peaked at 7.3 
and 6.6 µg/mL on days 1 and 2 of treatment, respectively, 
with corresponding AUC values of 2.3 and 1.1 mg/mL min 
observed. Carboplatin Cl values of 4.4 mL/min (1.8 mL/
min/kg) on day 1 of treatment and 9.4 mL/min (3.8 mL/
min/kg) on day 2 were calculated. These values compare 
with previously published data from infant neuroblastoma 
patients aged between 2 and 14 months of age, which 
showed a range of carboplatin Cl values of 12.8–33.6 mL/
min (2.1–3.5 mL/min/kg) and achievement of AUC val-
ues of 1.4–3.1 mg/mL min following a carboplatin dose of 
6.6 mg/kg recommended for children <12 kg [15].
Etoposide concentrations determined in patient 003 fol-
lowing a dose of 3.2 mg/kg peaked at a plasma concen-
tration of 6.1 µg/mL at the end of a 4-h intravenous infu-
sion. Table 4 shows the key pharmacokinetic parameters 
for etoposide in this patient studied at a gestational age of 
40 weeks. Etoposide Cl was 1.95 mL/min (0.78 mL/min/
kg), with an observed AUC value of 4.1 mg/mL min. These 
values compare to reported AUC values ranging from 3.4 to 
11.0 mg/mL min and Cl values of 3.2–13.0 mL/min (0.46–
1.45 mL/min/kg) in a previous study investigating etopo-
side pharmacokinetics in infant patients aged 2–14 months 
of age, following an etoposide dose of 5 mg/kg/day admin-
istered as a 2-h infusion.
Treatment response and toxicity
Patient 001 received a total of six courses of cisplatin, 
with the dose increased on course 2 based on plasma 
Table 2  Pharmacokinetic parameters for unbound and total cisplatin following administration of 1.8 mg/kg (course 1) and 2.7 mg/kg (course 2) 
cisplatin as a 24-h intravenous infusion to a 2-week-old neonate
Cisplatin dose (mg/kg) Total cisplatin Unbound cisplatin
Cmax (µg/mL) AUC0–∞ (µg/mL min) Cl (mL/min/kg) Cmax (µg/mL) AUC0–∞ (µg/mL min) Cl (mL/min/kg)
1.8 0.56 1433 1.24 0.08 168 10.6
2.7 1.36 5756 0.47 0.16 266 10.1
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Fig. 2  Relationship between patient body weight and unbound cispl-
atin clearance normalised to body weight in a paediatric patient popu-
lation (data from a previously published study [17] with data included 
from patient 001 shown in red)
Fig. 3  Plasma concentrations of vincristine measured in patient 
002 following short intravenous administration of a single dose of 
0.75 mg/m2 (0.05 mg/kg)
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concentrations observed on course 1. The increased dose 
level of 2.7 mg/kg was then maintained for courses 3–6 of 
treatment with no grade 3/4 toxicities reported. The patient 
responded well to cisplatin monotherapy, allowing com-
plete surgical resection, and is now in complete remission 
3.5 years from the end of treatment. Patient 002 received 
weekly vincristine for 10 weeks post-nephrectomy, follow-
ing diagnosis of Wilms’ tumour on day 2 of life. No tox-
icities were observed following treatment and the patient 
remains in remission at 2 years of age. Patient 003 was suf-
fering from anuria at the time of treatment and died 6 days 
after the start of chemotherapy with hepatomegaly, coag-
ulopathy, haemodynamic compromise and renal failure 
related to disease progression.
Discussion
Administration of the most appropriate doses of anticancer 
drugs to neonates within the first few weeks of life repre-
sents a significant clinical challenge. Dose adjustments rec-
ommended in clinical trial and treatment protocols are gen-
erally extrapolated from experience in dosing older infants. 
While it may be unrealistic to design large prospective 
clinical trials to generate data in large numbers of children 
within this defined population, it is essential that clinical 
pharmacology data generated are published to help guide 
future patient treatment. This is particularly important bear-
ing in mind the potential impact of ontogeny on expression 
of drug transporters and hence drug disposition, which is 
likely to be most relevant to neonates and preterm infants 
[18]. Without the publication of case reports and minimal 
datasets on small numbers of patients, clinicians will con-
tinue to struggle with the same concerns and uncertain-
ties when treating preterm infants and neonates with can-
cer, and the actual impact of ontogeny on drug disposition 
will be difficult to assess. In order to improve the knowl-
edge base in this area and have a real impact on clinical 
treatment, international collaboration and sharing of data 
will be required, ideally in the form of a single accessible 
database.
In the current study, we report on pharmacokinetic data 
for the anticancer drugs cisplatin, vincristine, etoposide and 
carboplatin, generated in two neonates being treated within 
the first 3 weeks of life and in a 32-week preterm infant 
treated at a gestational age of 40 weeks. It is currently com-
mon practice to dose infant patients (less than 1 year of 
age) based on BW, alongside additional dose reductions, 
such as a 50 % dose reduction for children <6 months of 
age [5, 19]. However, this may not necessarily be the most 
clinically advantageous approach [19, 20]. While it is 
essential that developing neonates are not subject to unnec-
essary side effects associated with their treatment, it is 
equally important that clinically meaningful exposures of 
drugs are achieved, in order for them to exhibit appropriate 
anti-tumour activity.
Treatment of a neonate diagnosed with hepatoblastoma 
at 2 weeks of age provided an opportunity to generate phar-
macokinetic data on cisplatin in this very young child, with 
a view to guiding therapy on course 2 of treatment in addi-
tion to providing information that may be useful for guid-
ing future patient treatment in similar clinical situations. As 
reported by van den Berg et al. [5], dose recommendations 
for cisplatin are difficult to provide due to the lack of phar-
macokinetic data published in infants. Following adminis-
tration of a recommended dose of 1.8 mg/kg on course 1 
of treatment in this patient, cisplatin levels were markedly 
lower than concentrations previously reported in the litera-
ture for children being treated for hepatoblastoma and other 
tumour types [12]. A 50 % dose increase to a dose level 
of 2.7 mg/kg was therefore implemented on course 2 of 
treatment, resulting in the achievement of plasma concen-
trations comparable to those previously reported in older 
children. As has previously been indicated for carboplatin 
[15], it may well be the case that cisplatin clearance values 
normalised for BW are proportionally higher in neonates 
and infants than in older children. Such differences may 
be related to a reduction in protein binding in neonates, 
Table 3  Pharmacokinetic parameters for vincristine following administration of 0.75 mg/m2 (0.05 mg/kg) vincristine as a short intravenous 
infusion in a 3-week-old neonate
Dose (mg/kg) Dose (mg) Cl (mL/min) Cl (mL/min/m2) AUC0–24h (ng/mL min) t1/2 (h) Vz (L)
0.05 0.16 29.8 142 4066 13.8 35.5
Table 4  Pharmacokinetic parameters for etoposide following administration of 3.2 mg/kg etoposide as a 4-h intravenous infusion in a preterm 
infant at an age of 8 weeks (gestational age of 40 weeks)
Dose (mg/kg) Dose (mg) Cl (mL/min) Cl (mL/min/kg) AUC0–∞ (mg/mL min) t1/2 (h) Vz (L)
3.2 8 1.95 0.78 4.1 5.8 1.0
691Cancer Chemother Pharmacol (2016) 77:685–692 
1 3
leading to a relative increase in renal and/or metabolic 
drug clearance, may be linked to differences in organ size 
relative to total body weight, or may reflect differences 
in ratios of fat, protein and intracellular water in this very 
young patient population. If this is the case, then these 
data would clearly not support the reduced dosing levels 
commonly proposed for these very young patients. While 
unbound cisplatin Cl was comparable between courses 1 
and 2 of treatment, a marked difference in total cisplatin Cl 
was observed between courses (1.24 mL/min/kg on course 
1 vs. 0.47 mL/min/kg on course 2), leading to a threefold 
increase in total cisplatin AUC. This could not be explained 
by a difference in albumin levels between course 1 and 2 
of treatment (22 vs. 25 g/L, respectively), although bili-
rubin levels were markedly elevated prior to treatment on 
course 1 but not course 2. The differences in total cisplatin 
pharmacokinetics observed between two courses of treat-
ment separated by only 2 weeks may indicate that constant 
monitoring of drug levels across sequential courses may be 
prudent for future neonate cancer patients.
Although it cannot be ruled out that the patient may have 
responded to treatment at the lower exposures observed, 
from a pharmacological perspective, such low cisplatin 
plasma concentrations would be a cause for concern and it 
is encouraging that the higher dose was well tolerated in 
this case. For the patient studied here, the increased dose 
of 2.7 mg/kg cisplatin was continued for courses 2–6 of 
treatment, with minimal toxicity observed, and the patient 
now remains in complete remission over 3 years following 
the end of treatment. This kind of TDM approach, utilising 
pharmacokinetic parameters to guide treatment, has previ-
ously been suggested for treating young patients with cis-
platin due to the uncertainties of currently available dosing 
guidelines [21].
In contrast to the results obtained following cisplatin 
treatment in a neonate, implementation of a 50 % dose 
reduction for a 3-week-old Wilms’ tumour patient being 
treated with vincristine resulted in achievement of a drug 
exposure comparable to values previously reported in older 
children [14]. The generation of these data in a TDM set-
ting provided the clinical team with the confidence to main-
tain this dose level for 10 weeks of treatment, leading to 
ongoing complete remission in the absence of significant 
toxicity. These findings are supported by data from a previ-
ous study by Crom et al. [22], including pharmacokinetic 
data obtained from twins aged 2 months, indicating that 
dosing should be based on BW as opposed to BSA in infant 
patients. In this neonate setting, a 50 % reduction in dose 
for vincristine would appear to be appropriate.
The final patient studied was a 32-week preterm infant 
diagnosed with stage 4S neuroblastoma and MYCN ampli-
fication, being treated at 8 weeks of age (gestational age 
of 40 weeks). Although this patient died only 6 days after 
the start of treatment, due to renal failure associated with 
disease progression, the pharmacokinetic data obtained 
again provide useful information in a rare and challenging 
clinical situation. Although carboplatin clearance values 
varied over the 2 days of pharmacokinetic sampling, they 
were comparable to those reported in previously studied 
infant neuroblastoma patients, resulting in the achievement 
of lower AUC values due to the lower dose of 4 mg/kg/
day implemented in this patient, as compared to a recom-
mended dose of 6.6 mg/kg [15]. Similarly, for etoposide, 
the dose utilised (3.2 mg/kg) was lower than a standard 
dose of 5 mg/kg recommended in infant neuroblastoma 
patients [15, 23]. The etoposide clearance value observed 
in the current study was within the range previously 
reported in infants (0.46–1.45 mL/min/kg) and older chil-
dren [15, 24], and the observed AUC therefore relatively 
low in comparison with this patient group, due to the lower 
dose administered. No conclusions can be drawn in rela-
tion to the pharmacokinetics of carboplatin and etoposide 
and clinical response or toxicity in this patient, as death due 
to disease progression occurred only days after treatment. 
In addition, the patient was receiving continuous veno-
venous haemofiltration (CVVH) before and after chemo-
therapy due to oligo-anuria and the impact of this on the 
pharmacokinetic parameters observed is unclear. However, 
the data generated would suggest that higher doses of car-
boplatin and etoposide may be beneficial in infant patients, 
assuming that they are appropriately tolerated. Indeed, this 
may be particularly relevant in the case of neonates being 
treated for stage 4S neuroblastoma, where outcome is 
extremely favourable if initial disease burden causing life-
threatening organ compromise can be overcome. In such 
a clinical situation, with a short window of opportunity to 
control rapidly growing abdominal disease in a high-risk 
situation, administration of the most appropriate and effec-
tive chemotherapy dosing regimen is likely to be critical.
The current report provides novel data on the pharma-
cokinetics of several widely used anticancer drugs in neo-
nates treated within the first few weeks of life and provides 
a comparison with data generated in older infants and chil-
dren where data are available. The provision of these clini-
cal pharmacology data in a challenging patient population 
acts as a useful reference point to support future dosing 
decisions to be made by clinicians in the treatment of pre-
term infants and neonates within the first few weeks of life. 
The generation and publication of datasets such as these 
provide useful clinical direction and are essential if we are 
to develop meaningful dosing guidance for commonly used 
anticancer drugs in this patient population. Such data will 
allow decisions to be made as to the most appropriate dos-
ing regimens to be utilised and identify which agents may 
require dose optimisation through TDM approaches on sin-
gle or multiple courses of treatment.
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